Your browser doesn't support javascript.
loading
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis.
Russler-Germain, David A; Cliff, Edward R Scheffer; Bartlett, Nancy L.
Afiliación
  • Russler-Germain DA; Division of Oncology, Washington University School of Medicine, St. Louis, MO.
  • Cliff ERS; Siteman Cancer Center, St. Louis, MO.
  • Bartlett NL; Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Blood ; 142(25): 2216-2219, 2023 12 21.
Article en En | MEDLINE | ID: mdl-37797275
ABSTRACT: Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Inmunoconjugados Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Inmunoconjugados Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article